logo
A Revolutionary War-era boat is being painstakingly rebuilt after centuries buried beneath Manhattan

A Revolutionary War-era boat is being painstakingly rebuilt after centuries buried beneath Manhattan

ALBANY, N.Y. (AP) — Workers digging at Manhattan's World Trade Center site 15 years ago made an improbable discovery: sodden timbers from a boat built during the Revolutionary War that had been buried more than two centuries earlier.
Now, over 600 pieces from the 50-foot (15-meter) vessel are being painstakingly put back together at the New York State Museum. After years on the water and centuries underground, the boat is becoming a museum exhibit.
Arrayed like giant puzzle pieces on the museum floor, research assistants and volunteers recently spent weeks cleaning the timbers with picks and brushes before reconstruction could even begin.
Though researchers believe the ship was a gunboat built in 1775 to defend Philadelphia, they still don't know all the places it traveled to or why it ended up apparently neglected along the Manhattan shore before ending up in a landfill around the 1790s.
'The public can come and contemplate the mysteries around this ship,' said Michael Lucas, the museum's curator of historical archaeology. 'Because like anything from the past, we have pieces of information. We don't have the whole story.'
From landfill to museum piece The rebuilding caps years of rescue and preservation work that began in July 2010 when a section of the boat was found 22 feet (7 meters) below street level.
Curved timbers from the hull were discovered by a crew working on an underground parking facility at the World Trade Center site, near where the Twin Towers stood before the 9/11 attacks.
The wood was muddy, but well preserved after centuries in the oxygen-poor earth. A previously constructed slurry wall went right through the boat, though timbers comprising about 30 feet (9 meters) of its rear and middle sections were carefully recovered. Part of the bow was recovered the next summer on the other side of the subterranean wall.
The timbers were shipped more than 1,400 miles (2,253 kilometers) to Texas A&M's Center for Maritime Archaeology and Conservation.
Each of the 600 pieces underwent a three-dimensional scan and spent years in preservative fluids before being placed in a giant freeze-dryer to remove moisture. Then they were wrapped in more than a mile of foam and shipped to the state museum in Albany.
While the museum is 130 miles (209 kilometers) up the Hudson River from lower Manhattan, it boasts enough space to display the ship. The reconstruction work is being done in an exhibition space, so visitors can watch the weathered wooden skeleton slowly take the form of a partially reconstructed boat.
Work is expected to finish around the end of the month, said Peter Fix, an associate research scientist at the Center for Maritime Archaeology and Conservation who is overseeing the rebuilding.
On a recent day, Lucas took time out to talk to passing museum visitors about the vessel and how it was found.
Explaining the work taking place behind him, he told one group: 'Who would have thought in a million years, 'someday, this is going to be in a museum?''
A nautical mystery remains
Researchers knew they found a boat under the streets of Manhattan. But what kind?
Analysis of the timbers showed they came from trees cut down in the Philadelphia area in the early 1770s, pointing to the ship being built in a yard near the city.
It was probably built hastily. The wood is knotty, and timbers were fastened with iron spikes. That allowed for faster construction, though the metal corrodes over time in seawater.
Researchers now hypothesize the boat was built in Philadelphia in the summer of 1775, months after the first shots of the Revolutionary War were fired at Lexington and Concord in Massachusetts. Thirteen gunboats were built that summer to protect Philadelphia from potential hostile forces coming up the Delaware River. The gunboats featured cannons pointing from their bows and could carry 30 or more men.
'They were really pushing, pushing, pushing to get these boats out there to stop any British that might start coming up the Delaware,' Fix said.
Historical records indicate at least one of those 13 gunboats was later taken by the British. And there is some evidence that the boat now being restored was used by the British, including a pewter button with '52' inscribed on it. That likely came from the uniform of soldier with the British Army's 52nd Regiment of Foot, which was active in the war.
It's also possible that the vessel headed south to the Caribbean, where the British redirected thousands of troops during the war. Its timbers show signs of damage from mollusks known as shipworms, which are native to warmer waters.
Still, it's unclear how the boat ended up in Manhattan and why it apparently spent years partially in the water along shore. By the 1790s, it was out of commission and then covered over as part of a project to expand Manhattan farther out into the Hudson River. By that time, the mast and other parts of the Revolutionary War ship had apparently been stripped.
'It's an important piece of history,' Lucas said. 'It's also a nice artifact that you can really build a lot of stories around.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is Danaher's M&A Premium Already Priced In?
Is Danaher's M&A Premium Already Priced In?

Yahoo

time9 minutes ago

  • Yahoo

Is Danaher's M&A Premium Already Priced In?

Danaher Corporation (NYSE: DHR) is a global science and technology innovator focused on designing, manufacturing, and marketing professional, medical, industrial, and commercial products and services. Following the 2023 spin-off of its Environmental & Applied Solutions segment (now Veralto), Danaher has transformed into a pure-play life sciences and diagnostics company, operating through three primary segments: Biotechnology, Life Sciences, and Diagnostics. Warning! GuruFocus has detected 4 Warning Signs with DHR. Biotechnology (~30% of FY2024 revenue) includes Danaher's bioprocessing and genomic reagents businesses, led by brands like Cytiva and Pall, serving pharmaceutical and biotech companies in biologics production and Sciences (~25% of revenue) offers analytical instruments, microscopy, and lab automation tools used by academic institutions, research labs, and clinical diagnostics developers. Key platforms include Leica Microsystems, SCIEX, and Beckman Coulter Life (~45% of revenue) comprises molecular diagnostics, core laboratory diagnostics, and point-of-care testing systems. Notably, Cepheidone of Danaher's flagship brandsoffers rapid molecular diagnostic testing platforms, particularly for infectious diseases like COVID-19, influenza, and tuberculosis. Danaher reported a better-than-feared quarter, beating both top and bottom line estimates significantly and maintaining its annual guidance. In Q1 FY2025, the company's total sales declined by 1% YoY to $5,741 million from $5,796 million in the previous year's quarter. The decline was due to -1.5% impact from foreign exchange translation, which was partially offset by 0.5% growth through acquisitions and flat core revenue growth. The revenue from the Biotechnology segment grew by 6% YoY to $1,612 million, driven by an increase in core sales from high-growth markets due to a rise in demand. The Life Sciences segment saw a decline of 3.5% YoY to $1,680 million due to a decrease in core sales in the genomics consumables business. Revenue from the Diagnostics segment declined by 3% YoY to $2,449 million due to a decline in the sales of the molecular diagnostic business and lower sales in the China region. The adjusted operating profit declined by 50 bps YoY to 29.6% in the quarter due to product mix, administrative cost structure, currency exchange rates, and acquisition Corporation's Growth & Cash Flow Danaher is positioned as a leading provider of life sciences, diagnostic, and biotechnology equipment after spinning off its environmental business (Veralto) in late 2023. Management's guidance for FY2025 assumes relatively stable end-market demand for the rest of the year (similar to Q1 levels). Against this backdrop, I believe Danaher should grow modestly in 2025, reflecting both macro headwinds (tariffs, academic budget cuts) and continued strength in critical segments. I have mentioned the guidance provided by the management below, and my thesis that should help the company achieve it. For fiscal 2025, Danaher reaffirmed core revenue growth of roughly +3% year-over-year. This is consistent with management's view that market demand (globally) will be relatively consistent with Q1, despite tariffs and other pressures. Adjusted diluted EPS guidance was set at $7.60$7.75 (vs. $7.68 consensus). Notably, management raised its Bioprocessing (biotech) growth forecast to the high-single-digits for 2025 (from a prior 67% outlook). Bioprocessing is Danaher's fastest-growing segment. Robust demand for biologic drug development kits and reagents drove higher Q1 results and should continue to drive growth for the remainder of FY2025. Furthermore, the segment is emerging from the destocking cycle, which should help drive sales. In contrast, the Life Sciences segment forecast was trimmed to essentially flat growth, as funding uncertainties slowed academic and government sales (particularly in the U.S.), and China's medical equipment sector has experienced some softness. This should offset the healthy growth in the Bioprocessing segment. However, any rebound in global R&D spending (or continued Chinese stimulus) could surprise on the upside. The Diagnostics segment (especially Cepheid's molecular tests) is expected to see modest growth: Cepheid's respiratory test sales are forecast to reach around $1.7 billion for 2025, but production volume will return to a normal seasonal level after Q1. Overall, Danaher's portfolio remains tilted toward high-growth medical and diagnostics markets, which underpins its steady outlook despite industry headwinds. A key uncertainty is trade policy: Danaher estimates that current U.S. and European tariffs could add roughly $350 million in costs in 2025. However, the company has long worked to offset these costs via its Danaher Business System (DBS), regionalized manufacturing, and pricing strategies. The company should absorb much of the tariff impact through cost actions and supply-chain adjustments (e.g., surcharges or shifting production) rather than curtailing R&D or major initiatives. Because Danaher's products (lab instruments, diagnostics, and biotech consumables) are often mission-critical in healthcare, I believe its end markets will remain resilient even under tariff pressure. In short, tariffs represent a moderate headwind, but Danaher should largely neutralize the impact by expense reductions and operational flexibility. Margins in the upcoming quarters are expected to contract largely due to seasonality in Cepheid's respiratory testing business. Cepheid is one of Danaher's higher?margin units, and Q2 respiratory kit revenue is assumed to be only about $250 million (vs. ~$625 million in Q1). This sharp seasonal drop in high-margin sales, plus normal diagnostic restructuring costs (e.g., the management of China's reimbursement changes), drives the lower quarter?on?quarter profit margin. In sum, I believe the company's margins should continue to decline and improve in the back half of 2025. As a company built on decades of disciplined capital deployment, Danaher's ability to acquire and successfully integrate businesses has been one of its defining competitive advantages. Flagship acquisitions like Cepheid and Pall have meaningfully strengthened Danaher's diagnostics and bioprocessing platforms, but they also introduce inherent integration risks. These include short-term pressures on margins, incremental R&D and SG&A costs, and the complexities of aligning acquired operations with Danaher's operating structure. While such challenges are typical of any acquisitive strategy, Danaher's track record sets it apart. Over the past 30 years, the company has repeatedly demonstrated its ability to extract synergies, improve productivity, and scale acquisitions effectively, largely driven by the Danaher Business System (DBS). This system institutionalizes continuous improvement, cost efficiency, and cultural integration across its portfolio. Though former CEO Larry Culp played a pivotal role in establishing this M&A discipline, the company's current leadership remains strongly committed to DBS principles, which continue to guide its post-acquisition integration efforts. Moreover, Danaher doesn't pursue acquisitions purely for scale; it focuses on high-quality, strategic assets that complement existing platforms and offer long-term value creation. While integration may temporarily weigh on profitability, especially in the form of restructuring expenses, near-term dilution, or elevated investments in innovation, these are often calculated trade-offs for future operating leverage and market expansion. In essence, what might be viewed as a risk is also one of Danaher's greatest strengths; its consistent ability to turn acquired assets into high-margin, growth-focused businesses that reinforce its leadership in life sciences and diagnostics. As of March 31, 2025, investor activity around Danaher reflected a balanced mix of strategic repositioning and continued confidence in the company's long-term potential. Notably, renowned value investors like Joel Greenblatt (Trades, Portfolio) (+29.03%), Wallace Weitz (Trades, Portfolio) (+23.17%), and Arnold Van Den Berg (Trades, Portfolio) (+14.62%) significantly increased their holdings, signaling optimism about Danaher's focused life sciences and diagnostics trajectory. Ken Fisher (Trades, Portfolio) also added modestly to his position (+1.23%), reinforcing steady institutional support. While some investors like Jefferies Group (Trades, Portfolio), Mario Gabelli (Trades, Portfolio), and George Soros (Trades, Portfolio) trimmed their stakes. Danaher is currently trading at a forward P/E of 25.5x and 22.9x on FY2025 and FY2026 estimated EPS of $7.70 and $8.57, respectively, which is below its five-year average forward P/E of 29.9x. On an EV/EBITDA basis, Danaher trades at approximately 18xhigher than peers such as Thermo Fisher Scientific (P/E ~15x, EV/EBITDA ~13x) and Agilent Technologies (P/E ~21x, EV/EBITDA ~15x). While Danaher's valuation premium may appear elevated relative to peers, it reflects the company's consistent execution, higher exposure to recurring revenue from consumables, and strong margin profile. The market seems cautiously optimistic, pricing in steady growth expectations. For FY2025, Danaher's outlook implies stable and controlled expansion, led primarily by strong bioprocessing demand. Although adjusted operating margins are expected to decline in Q2 due to seasonal normalization in the high-margin Cepheid business, a recovery is anticipated in the latter half of the year. Danaher's long-standing execution discipline, anchored by the Danaher Business System (DBS), equips it to offset macro pressures through operational efficiency and agile supply chain management. With a focused portfolio in mission-critical life sciences and diagnostics, Danaher remains well-positioned to deliver modest yet resilient growth in 2025, supported by strategic capital deployment and a strong competitive moat. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

HII Christens Guided Missile Destroyer Jeremiah Denton (DDG 129)
HII Christens Guided Missile Destroyer Jeremiah Denton (DDG 129)

Yahoo

time29 minutes ago

  • Yahoo

HII Christens Guided Missile Destroyer Jeremiah Denton (DDG 129)

PASCAGOULA, Miss., June 28, 2025 (GLOBE NEWSWIRE) -- HII (NYSE: HII) christened today the future USS Jeremiah Denton (DDG 129), the third Flight III Arleigh Burke-class destroyer to be built at the company's Ingalls Shipbuilding division. The ship's name honors former U.S. Sen. Jeremiah Denton Jr., a Vietnam War veteran who was awarded the Navy Cross for his heroism as a prisoner of war. Denton spent 34 years as a naval aviator, including eight years as a prisoner of war in Vietnam. He is known for his act of genius during a televised broadcast in captivity, when Denton spelled out the word 'torture' through Morse code using his eyes to blink the code. Following his Navy career, Denton was elected to the U.S. Senate representing his home state of Alabama in 1980. 'Today, we honor the skilled work of our Ingalls shipbuilders and the enduring spirit of Adm. Jeremiah Denton, a man who, under unimaginable pressure, exemplified strength, sacrifice, leadership and resilience,' Ingalls Shipbuilding President Brian Blanchette said. 'When we christen a ship, we celebrate a joint mission with our Navy industry partners, one that connects the work we do here in Pascagoula to the safety and security of our nation and the free world.' Acting Assistant Secretary of the Navy for Research Development and Acquisition Brett Seidle was the keynote speaker. He highlighted the importance of naval ships, the legacy of the ship's namesake, and recognized the shipbuilding workforce as a vital national asset. Photos accompanying this release are available at: 'Today we christen not just a ship, but we make a statement — a powerful steel forged testament to America resolve,' Seidle said. 'The future USS Jeremiah Denton will sail as a reminder to the world, much like her namesake, the United States does not back down. The United States does not break and we do not forget our heroes. That is the legacy that this warship carriers forward.' The ship's co-sponsors and daughters of the namesake, Madeleine Denton Doak and Mary Denton Lewis, performed the traditional bottle-breaking ceremony against the bow to formally christen the ship. Madeline represented the family by providing remarks and paying tribute to her late father and mother who were Alabama natives. 'This magnificent ship was built by their neighbors (Mississippi), men and women who understand their skills, hard work and precise attention to detail that are vital in keeping our world safe.' Flight III Arleigh Burke-class destroyers represent the next generation of surface combatants and incorporate a number of design modifications that collectively provide significantly enhanced capability. Upgrades include the AN/SPY-6(V)1 Air and Missile Defense Radar (AMDR) and the Aegis Baseline 10 Combat System required to keep pace with the threats well into the 21st century. Ingalls has delivered 35 Arleigh Burke-class destroyers to the U.S. Navy including the first Flight III, USS Jack H. Lucas (DDG 125), in June of 2023. In addition, Ingalls Shipbuilding has five Flight IIIs currently under construction including Ted Stevens (DDG 128), Jeremiah Denton (DDG 129), George M. Neal (DDG 131), Sam Nunn (DDG 133) and Thad Cochran (DDG 135). Video of the ceremony, along with additional information on DDG 129, and the Arleigh Burke-class program, can be found at Jeremiah Denton (DDG 129) Christening - HII. About HII HII is a global, all-domain defense provider. HII's mission is to deliver the world's most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world. As the nation's largest military shipbuilder, and with a more than 135-year history of advancing U.S. national security, HII delivers critical capabilities extending from ships to unmanned systems, cyber, ISR, AI/ML and synthetic training. Headquartered in Virginia, HII's workforce is 44,000 strong. For more information, visit: HII on the web: HII on Facebook: HII on X: HII on Instagram: HII Contact: Kimberly K. A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store